Dashboard
Manage Tickers

CMPSCOMPASS Pathways plc

Nasdaq compasspathways.com


$ 7.20 $ -0.21 (-2.83 %)    

Monday, 16-Sep-2024 15:49:40 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 473.20 $ 0.14 (0.03 %)
DIA $ 417.26 $ 0.30 (0.07 %)
SPY $ 562.61 $ 1.14 (0.2 %)
TLT $ 101.29 $ 0.66 (0.65 %)
GLD $ 238.59 $ -0.01 (-0.01 %)
$ 7.25
$ 7.41
$ 7.20 x 100
-- x --
$ 7.15 - $ 7.41
$ 5.01 - $ 12.75
442,438
na
495.81M
$ 1.53
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-01-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 02-29-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-03-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 02-28-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-10-2022 03-31-2022 10-Q
11 02-24-2022 12-31-2021 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

mdma-therapy-for-ptsd-faces-fda-delay-are-there-other-ways-forward
MDMA Therapy For PTSD Faces FDA Delay: Are...
09/13/2024 00:28:49

rbc-capital-reiterates-outperform-on-compass-pathways-maintains-23-price-target
RBC Capital Reiterates Outperform on Compa...
09/10/2024 14:43:44

RBC Capital analyst Leonid Timashev reiterates Compass Pathways (NASDAQ:CMPS) with a Outperform and maintains $23 price target.

cantor-fitzgerald-reiterates-overweight-on-compass-pathways
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 16:59:11

Cantor Fitzgerald analyst Charles Duncan reiterates Compass Pathways (NASDAQ:CMPS) with a Overweight.

shake-up-at-lykos-therapeutics-after-fda-blocks-ecstasy-based-treatment-ceo-steps-down
Shake Up At Lykos Therapeutics After FDA B...
09/05/2024 21:31:40

Lykos Therapeutics CEO Amy Emerson steps down following the FDA's rejection of the company's MDMA-based PTSD therapy.

psychedelic-drugs-market-set-to-grow-by-137b-by-2028-driven-by-mental-health-disorders-and-ai-integration
Psychedelic Drugs Market Set To Grow By $1...
09/05/2024 16:53:46

The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI adva...

galapagos-xpeng-cormedix-and-other-big-stocks-moving-higher-on-monday
Galapagos, XPeng, CorMedix And Other Big S...
08/26/2024 13:59:41

hc-wainwright--co-reiterates-buy-on-compass-pathways-maintains-120-price-target
HC Wainwright & Co. Reiterates Buy on Comp...
08/23/2024 11:34:33

HC Wainwright & Co. analyst Patrick Trucchio reiterates Compass Pathways (NASDAQ:CMPS) with a Buy and maintains $120 pri...

canaccord-genuity-maintains-buy-on-compass-pathways-lowers-price-target-to-48
Canaccord Genuity Maintains Buy on Compass...
08/02/2024 11:46:36

Canaccord Genuity analyst Sumant Kulkarni maintains Compass Pathways (NASDAQ:CMPS) with a Buy and lowers the price target fr...

compass-pathways-q2-2024-gaap-eps-056-misses-052-estimate
Compass Pathways Q2 2024 GAAP EPS $(0.56) ...
08/01/2024 10:32:59

hc-wainwright--co-reiterates-buy-on-compass-pathways-maintains-120-price-target
HC Wainwright & Co. Reiterates Buy on Comp...
07/31/2024 12:18:57

HC Wainwright & Co. analyst Patrick Trucchio reiterates Compass Pathways (NASDAQ:CMPS) with a Buy and maintains $120 pri...

rbc-capital-initiates-coverage-on-compass-pathways-with-outperform-rating-announces-price-target-of-23
RBC Capital Initiates Coverage On Compass ...
07/23/2024 10:42:40

RBC Capital analyst Leonid Timashev initiates coverage on Compass Pathways (NASDAQ:CMPS) with a Outperform rating and announ...

Core News & Articles
'MDMA Therapy Gets Support From Prominent ...
07/16/2024 18:51:34

https://www.greenmarketreport.com/mdma-therapy-gets-support-from-prominent-research-group-as-fda-weighs-action/ The paper noted...

cantor-fitzgerald-reiterates-overweight-on-compass-pathways
Cantor Fitzgerald Reiterates Overweight on...
06/21/2024 16:27:30

Cantor Fitzgerald analyst Charles Duncan reiterates Compass Pathways (NASDAQ:CMPS) with a Overweight.

Core News & Articles
'Oregon's First-In-Nation Psilocybin Indus...
06/12/2024 18:07:09

https://www.marijuanamoment.net/oregons-first-in-nation-psilocybin-industry-is-struggling-to-find-paying-customers-a-year-after...

why-lands-end-shares-are-trading-lower-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why Lands' End Shares Are Trading Lower? H...
06/05/2024 17:04:26

whats-going-on-with-mindmed-and-psychedelic-stocks
What's Going On With MindMed And Psychedel...
06/05/2024 14:58:55

Mind Medicine (MindMed) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approv...

douyu-international-posts-q1-results-joins-annexon-dollar-tree-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session
DouYu International Posts Q1 Results, Join...
06/05/2024 12:07:39

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
06/05/2024 12:06:43

why-stitch-fix-shares-are-trading-higher-by-18-here-are-20-stocks-moving-premarket
Why Stitch Fix Shares Are Trading Higher B...
06/05/2024 09:27:25

gsk-boston-beer-and-other-big-stocks-moving-lower-in-mondays-pre-market-session
GSK, Boston Beer And Other Big Stocks Movi...
06/03/2024 12:13:57

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION